Harga 2 Obat Rekomendasi Terbaru WHO untuk Pasien Covid-19, Tembus Jutaan Rupiah

Any Hidayati

Editor:

  • WHO merekomendasikan Actemra dan Kevzara untuk obat Covid-19.
  • Actemra dibandrol dengan harga Rp1.162.200 dan Rp5.710.600 tergantung dosis.
  • Kevzara belum resmi masuk Indonesia tapi di AS dipatok dengan harga sekitar Rp55 juta untuk dosis 150mg/1,14ml.

SKOR.id - Selasa (6/7/2021), Badan Kesehatan Dunia (WHO) merekomendasikan dua jenis obat radang sendi untuk pengobatan Covid-19.

Dilansir dari Reuters.com, obat yang dimaksud oleh WHO tersebut adalah Actemra dari Roche dan Kevzara dari Sanofi.

Kedua obat tersebut telah diuji WHO kepada 10.930 pasien Covid-19 kategori berat dan kritis yang mana pasien yang mendapat suntikan salah satu obat tersebut memiliki progres positif ketimbang yang hanya mendapat perawatan biasa.

Sebanyak 6.449 orang menggunakan salah satu obat radang sendi tersebut memiliki kemungkinan hidup lebih besar dari 4.481 orang lainnya hanya mendapat perawatan biasa selama 28 hari pengujian tersebut.

Dilansir dari Kompas.com, obat jenis Acterma dapat mengatasi badai sitokin atau respon berlebihan tubuh terhadap infeksi ketika terpapar Covid-19.

Sehingga kerusakan organ tubuh akibat badai sitokin saat terpapar Covid-19 dapat ditekan karena menurunkan beberapa penanda inflamasi atau peradangan.

Meskipun telah teruji klinis, Actemra dan Kevzara adalah obat radang sendi yang tergolong obat keras.

Sehingga obat tersebut harus mendapat pengawasan ketat dari dokter atau tenaga kesehatan selama proses pemulihan.

Badan pengawas obat dan makanan Amerika Serikat telah memberikan izin edar untuk dua jenis obat tersebut sejak pekan lalu.

Di Indonesia, baru Actemra yang telah resmi beredar di pasaran dan mendapat izin edar dari Badan Pengawas Obat dan Makanan (BPOM).

Actemra atau Tocilizumab dosis 400mg/20ml dijual dengan harga Rp5.710.600. Sedangkan, dosis 80mg/4ml dibandrol dengan harga Rp1.162.200.

Kevzara di Amerika Serikat dipatok dengan harga 3.827 dolar AS atau setara Rp55 juta untuk dosis 150mg/1,14ml.

Walaupun telah direkomendasikan oleh WHO, dua obat radang sendi tersebut mempunyai beberapa efek samping untuk pemakainya.

Dilansir dari KATADATA Indonesia, kedua obat tersebut memiliki efek samping antara lain, infeksi pernapasan, sakit kepala, tekanan darah tinggi, peningkatan enzim hati, dan alergi.

Ikuti juga InstagramFacebookYouTube, dan Twitter dari Skor Indonesia.

Berita Covid-19 Lainnya:

Mengenal Perbedaan Sinovac dan AstraZeneca, 2 Vaksin yang Dipakai di Indonesia

Catat, Hal yang Perlu Diperhatikan Sebelum dan Setelah Vaksinasi Covid-19

Source: KompasReutersKata Data

RELATED STORIES

5 Bintang NBA yang Gagal Lolos ke Olimpiade Tokyo, 2 MVP Jadi Korban

5 Bintang NBA yang Gagal Lolos ke Olimpiade Tokyo, 2 MVP Jadi Korban

Ada beberapa pemain asing NBA yang berstatus bintang namun absen di Olimpiade 2020 Tokyo karena negaranya tak lolos

3 Rekomendasi Olahraga saat Isolasi Mandiri dengan Gejala Ringan Covid-19

Demi menjaga diri dan lingkungan sekitar, masyarakat yang mengalami gejala ringan-sedang Covid-19 disarankan untuk melakukan isolasi mandiri.

Skor co creators network
RIGHT_ARROW
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
PLAY_ICON
RIGHT_ARROW

THE LATEST

Pemain Timnas Putri Indonesia, Claudia Scheunemann, resmi dikontrak FC Utrecht Vrouwen. (Foto: Dok. FC Utrecht/Grafis: Deni Sulaeman/Skor.id)

National

Beri Kontrak Jangka Panjang, FC Utrecht Nilai Claudia Scheunemann sebagai Aset Berharga

Pemain Timnas Putri Indonesia, Claudia Scheunemann, resmi dikontrak FC Utrecht Vrouwen hingga 2028.

Rais Adnan | 12 Aug, 10:36

Persib vs Manila Digger (AFC Champions League 2 2025-2026). (Grafis: Deni Sulaeman/Skor.id)

National

Prediksi dan Link Live Streaming Persib vs Manila Digger di Play-Off AFC Champions League 2 2025-2026

Laga Persib vs Manila Digger akan digelar di Stadion GBLA, Bandung, Rabu (13/8/2025).

Rais Adnan | 12 Aug, 08:31

aji santoso legenda sepak bola indonesia

Liga 2

Grup Timur Ketat, Aji Santoso Coba Beberapa Formasi untuk Persela Lamongan

Pelatih Persela, Aji Santoso, terus mempersiapkan timnya untuk Championship 2025-2026.

Rais Adnan | 12 Aug, 07:03

Gervane Kastaneer (Persib Bandung). (Hendy Andika/Skor.id)

Liga 1

Ini Faktor yang Buat Eks Striker Asing Persib Gabung Persis Solo

Gervane Kastaneer resmi dikontrak Persis Solo hingga akhir musim 2025-2026.

Rais Adnan | 12 Aug, 06:32

cover persib

Liga 1

Alasan Persib Gunakan Jersey Alternatif Lawan Manila Digger

Persib bakal menghadapi Manila Digger pada play-off ACL 2 2025-2026 di Stadion GBLA, Rabu (13/8/2025).

Rais Adnan | 12 Aug, 06:19

Update bursa transfer Liga Italia (Serie A) musim 2025-2026. (Deni Sulaeman/Skor.id).

Liga Italia

Update Bursa Transfer Liga Italia 2025-2026

Update bursa transfer Liga Italia (Serie A) musim 2025-2026, Napoli, Inter Milan, Juventus, hingga AC Milan berburu pemain baru.

Pradipta Indra Kumara | 12 Aug, 04:21

Update bursa transfer La Liga (Liga Spanyol) di musim 2025-2026. (Grafis: Deni Sulaeman/Skor.id).

La Liga

Update Bursa Transfer La Liga 2025-2026

Update bursa transfer La Liga (Liga Spanyol) musim 2025-2026, Real Madrid, Barcelona, hingga Atletico Madrid beruburu pemain baru.

Pradipta Indra Kumara | 12 Aug, 04:01

Update bursa transfer Liga Inggris (Premier League) musim 2025-2026. (Grafis: Deni Sulaeman/Skor.id).

Liga Inggris

Update Bursa Transfer Liga Inggris 2025-2026

Berikut ini update bursa transfer Liga Inggris (Premier League) musim 2025-2026.

Pradipta Indra Kumara | 12 Aug, 03:27

La Liga 2025-2026 (Liga Spanyol). (Grafis: Deni Sulaeman/Skor.id).

La Liga

La Liga 2025-2026: Jadwal, Hasil dan Klasemen Lengkap

Jadwal, hasil, dan klasemen La Liga 2025-2026 (Liga Spanyol), yang akan diperbarui seiring kompetisi.

Pradipta Indra Kumara | 12 Aug, 02:22

Liga Italia (Serie A) musim 2025-2026. (Grafis: Deni Sulaeman/Skor.id).

Liga Italia

Liga Italia 2025-2026: Jadwal, Hasil dan Klasemen Lengkap

Jadwal, hasil, dan klasemen lengkap Liga Italia 2025-2026 yang diperbarui seiring berjalannya kompetisi.

Pradipta Indra Kumara | 12 Aug, 02:21

Load More Articles